# Progesterone induced immune modulation during pregnancy

> **NIH NIH R01** · CINCINNATI CHILDRENS HOSP MED CTR · 2020 · $774,922

## Abstract

Abstract. Pregnancy outwardly stimulates an assortment of changes in mothers that work together for creating
the anatomical space that accommodates growth, nutrient exchange and elimination of waste products for the
developing fetus. However, considering intimate physical approximation of maternal with fetal tissues which
are genetically discordant, immunological changes that prevent mother’s immune cells from attacking and
rejecting foreign fetal tissues are equally important. Unfortunately, how these immunological shifts work and
what stimulates them during pregnancy remain poorly undefined. With these fundamental gaps in knowledge
pertaining to how reproduction works unresolved, it should be no surprise that pregnancy complications remain
the leading cause of infant and childhood mortality. We propose a more comprehensive understanding of how
pregnancy works, integrating immunological with other physiological changes, is urgently needed for filling
these knowledge gaps and uncovering new, more effective strategies for mitigating pregnancy complications.
Our central hypothesis is that progesterone, the female reproductive hormone essential for maintaining uterine
quiescence (averting premature uterine emptying), also promotes maternal immunological adaptations
required for sustaining healthy term pregnancy. This hypothesis is based on increasingly recognized immune-
modulatory properties for this highly conserved reproductive hormone. Our preliminary studies show
progesterone drives differentiation of CD4+ T cells into an immune suppressive regulatory phenotype. The
proportion of maternal regulatory T cells increase in the circulation and at the maternal-fetal interface during
healthy pregnancy, whereas a variety of complications linked with disrupted fetal tolerance (e.g. prematurity,
preeclampsia, miscarriage) are associated with blunted expansion of these cells. Maternal regulatory T cells
expansion is similarly overturned with abortion induced by the nuclear progesterone receptor antagonist, RU-
486. We also find a variety of maternal immune cells in systemic lymphoid tissues and at the maternal-fetal
interface express the canonical nuclear progesterone receptor. This includes maternal regulatory T cells, and
in particular those recognizing genetically foreign fetal-expressed antigens. Reciprocally, selective loss of
progesterone receptor in maternal regulatory T cells blunts their expansion during pregnancy causing fetal
wastage. Based on these exciting proof-of-concept preliminary findings showing the protective benefits of
progesterone stimulation of maternal immune cells, the following aims will more comprehensively investigate
progesterone induced systemic and local immunological changes required for maintaining pregnancy. Aim 1
will investigate the tempo of progesterone responsiveness amongst maternal immune cells during pregnancy.
Aim 2 will define which maternal immune cell subsets require progesterone responsiveness for maintaining...

## Key facts

- **NIH application ID:** 9969321
- **Project number:** 5R01AI145840-02
- **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR
- **Principal Investigator:** Sing Sing Way
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $774,922
- **Award type:** 5
- **Project period:** 2019-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9969321

## Citation

> US National Institutes of Health, RePORTER application 9969321, Progesterone induced immune modulation during pregnancy (5R01AI145840-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9969321. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
